奥曲肽联合前列地尔治疗急性胰腺炎临床效果观察.docVIP

奥曲肽联合前列地尔治疗急性胰腺炎临床效果观察 　　摘 要：目的 ：探讨奥曲肽联合前列地尔治疗急性胰腺炎（AP）临床疗效。方法： 选取我院2013年1月-2014年6月收治的急性胰腺炎患者59例，随机分为两组，对照组29例，观察组30例，对照组患者采用奥曲肽治疗，观察组患者联合应用奥曲肽和前列地尔，观察比较两组患者治疗的的临床疗效和并发症发生情况。结果： 观察组治疗1周后总有效率达93.3%（28/30），对照组总有效率为72.4%（21/29），差异显著（P0.05）;观察组并发症发生率为6.7%（2/30）,明显低于对照组的20.7%（6/29），差异有统计学意义（P0.05）。结论： 联用奥曲肽和前列地尔治疗急性胰腺炎具有显著的疗效，能有效改善患者的生命体征和临床症状，减少并发症的发生，值得在临床上进一步推广。 　　关键词：奥曲肽；前列地尔；急性胰腺炎 　　Abstract： Objective To evaluate the clinical efficacy of octreotide alprostadil treatment of acute pancreatitis (AP). Methods 59 cases of acute pancreatitis in our hospital patients in January 2013 -2014 in June admitted, were randomly divided into two groups, a control group of 29 patients, 30 patients in the control group of patients in the observation group using octreotide treatment, the observation group were combined octreotide and alprostadil, the two groups were observed and compared the clinical efficacy of treatment and complications were observed. The results observed after 1 week of treatment group total effective rate was 93.3% (28/30), the control group, the total effective rate was 72.4% (21/29), the difference was significant (P0.05); observation group complication rate was 6.7% (2/30), significantly lower than the 20.7% in the control group (6/29), the difference was statistically significant (P0.05). Conclusion combined with octreotide and alprostadil treatment of acute pancreatitis have a significant effect, can effectively improve the lives of patients with signs and symptoms, reduce complications, worthy of further promotion in clinical practice. 　　Keywords: Octreotide; alprostadil; acute pancreatitis 　　急性胰腺炎（AP）是常见的内科急症，通常伴有全身炎性反应综合征，严重者还伴有多器官功能衰竭[1]。目前，奥曲肽和前列地尔均是临床常用药，有助于加快胰腺素的分泌，改善胰腺微循环，但是单一使用奥曲肽或前列地尔往往得不到较好的治疗效果。为了进一步提高急性胰腺炎的治愈率，本次研究联用奥曲肽和前列地尔，效果理想，现将结果报告如下。 　　1 资料与方法 　　1.1一般资料 59例研究对象均为2013年1月-2014年6月期间在我院接受治疗的急性胰腺炎患者，随机分为对照组和观察组。其中男性33例，女性26例，年龄19-72岁，平均年龄（46.6±11.5）岁；病程0.3h-4d，平均病程（1.6±0.4）d。47例轻症胰腺炎，12例重症胰腺炎。两组患者在性别、年龄、病程等一般资料无明显差异（P0.05），具有可比性。